- $96.32bn
- $98.93bn
- $32.24bn
- 98
- 36
- 80
- 82
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 27,978 | 26,134 | 28,945 | 29,446 | 32,235 |
Cost of Revenue | |||||
Gross Profit | 8,960 | 8,011 | 9,538 | 9,734 | 11,279 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 26,040 | 24,703 | 23,227 | 26,109 | 27,364 |
Operating Profit | 1,938 | 1,431 | 5,718 | 3,337 | 4,871 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,862 | 841 | 5,787 | 3,394 | 4,778 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,090 | 345 | 4,730 | 2,637 | 3,848 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 1,439 | 5,146 | 4,546 | 2,475 | 3,745 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 1,439 | 5,146 | 4,546 | 2,475 | 3,745 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.634 | 0.377 | 1.5 | 1.64 | 2.1 |
Dividends per Share |